Medpace price to book ratio MEDP

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 43.1×
10-year median: 7.5×
Against its 10-year history: 94th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.5× to 86.8×
Peer median: 3.6×

Medpace's price to book ratio is 43.1× as of Oct 23, 2026.

That is above its ten-year median of 7.5×, higher than on 94% of days in the last ten years.

Over that time it ranged from 1.5× in May 2017 to 86.8× in Oct 2025.

The median for 10 diagnostics and research stocks of a similar size is 3.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	43.1×	19.6×	58.6×
2025	54.4×	10.6×	86.8×
2024	12.0×	11.0×	22.5×
2023	20.0×	14.1×	21.9×
2022	18.9×	5.2×	20.0×
2021	8.7×	6.0×	9.1×
2020	6.3×	3.3×	6.3×
2019	4.4×	3.1×	4.7×
2018	3.3×	2.3×	4.1×
2017	2.5×	1.5×	2.5×
2016	2.4×	2.1×	2.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.

Company	Price to book ratio
MEDPMedpace	43.1×
RVTYRevvity	2.5×
LHLabcorp	3.1×
DGXQuest Diagnostics	3.6×
MTDMettler-Toledo International	n/m
BIOBio-Rad Laboratories	1.4×
CAICaris Life Sciences	15.3×
ILMNIllumina	14.3×
IDXXIDEXX Laboratories	27.4×
WATWaters	2.9×
IQVIQVIA	7.5×
Peer median	3.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Medpace

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.